Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Hologic Inc Price T Rowe Associates Inc increased Position

Price T Rowe Associates Inc increased Position in Hologic Inc

Price T Rowe Associates Inc has filled a SC 13G/A form regarding Hologic Inc . Filing Link: 000008025516001251. Per Price T Rowe Associates Inc ’s filing, the filler reported increased stake in the company by 44.94 % to 28,648,444 shares. Price T Rowe Associates Inc now owns 10.2% of the Health Care-company. This form was required due to trading activity on May 31, 2016.

The $689.00 billion institutional investor looks more positive after such an increase of Hologic Inc’s position.

Hologic Inc Hedge Funds Ownership

Latest SEC filings show 375 hedge funds and institutional investors own Hologic Inc. The institutional ownership of the company in Q1 2015 is very high, at 95.39 % of the shares outstanding. They decreased by 3535310 the total shares they hold. As of that quarter these institutional investors owned 265989527 shares. A total of 63 funds opened new positions in Hologic Inc and 118 increased their holdings. There were 41 funds that closed their positions and 132 that reduced them.

HEDGE-FUNDS-LIST-DATABASE-FREE Exchange Capital Management Inc is the most positive institutional investor on Hologic Inc, with ownership of 932 shares as of Q1 2015 for 0.01% of the fund’s portfolio. King Investment Advisors Inc is another positive player owning 335342 shares of the company or 4.27% of their stocks portfolio. CA Relational Investors Llc have 18.02% of their stock portfolio invested in the stock for 12968332. Further, Partner Investment Management Lp disclosed it had purchased a stake worth 2.73% of the fund’s stock portfolio in the company. The NY Icahn Carl C was also a notable investor in the firm, owning 34154879 shares. Hologic Inc is 3.52% of the fund’s stock portfolio.

Company Profile

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays. Its Breast Health products include a portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection for mammography and minimally invasive breast biopsy devices, breast biopsy site markers and breast biopsy guidance systems. Its GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. Its Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers.

Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.

Price T Rowe Associates Inc website.

The post Hologic Inc Price T Rowe Associates Inc increased Position appeared first on Octafinance.

This post first appeared on Octafinance – Financial News, Reports And Intell, please read the originial post: here

Share the post

Hologic Inc Price T Rowe Associates Inc increased Position


Subscribe to Octafinance – Financial News, Reports And Intell

Get updates delivered right to your inbox!

Thank you for your subscription